Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15709429 | 0.98 | FOLH1 (0.40) | OPRD1FOLH1GRIN1GRIN2AGRIN2B | |
| SCHEMBL15047602 | 0.84 | SIGMAR1 (0.42) | FOLH1L3MBTL1CYP2D6GAASMN1; SMN2 | |
| SCHEMBL16925972 | 0.83 | GRIN1 (0.47) | OPRD1FOLH1GRIN1GRIN2AGRIN2B | |
| SCHEMBL27143361 | 0.83 | GRIN1 (0.48) | OPRD1FOLH1GRIN1GRIN2AGRIN2B | |
| SCHEMBL1079076 | 0.83 | GRIN1 (0.48) | OPRD1FOLH1GRIN1GRIN2AGRIN2B | |
| SCHEMBL999924 | 0.83 | GRIN1 (0.48) | OPRD1FOLH1GRIN1GRIN2AGRIN2B | |
| SCHEMBL16925973 | 0.83 | GRIN1 (0.48) | OPRD1FOLH1GRIN1GRIN2AGRIN2B | |
| SCHEMBL5864681 | 0.83 | GRIN1 (0.48) | OPRD1FOLH1GRIN1GRIN2AGRIN2B | |
| SCHEMBL210579 | 0.83 | GRIN1 (0.48) | OPRD1FOLH1GRIN1GRIN2AGRIN2B | |
| SCHEMBL15709382 | 0.82 | SIGMAR1 (0.43) | FOLH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140314670-A1 | CLICKED SOMATOSTATIN CONJUGATED ANALOGS FOR BIOLOGICAL APPLICATIONS | UNIVERSITE DE CERGY PONTOISE (FR) | 2014-10-23 | — | — | US | disclosed |
| US-20140314670-A1 | CLICKED SOMATOSTATIN CONJUGATED ANALOGS FOR BIOLOGICAL APPLICATIONS | UNIVERSITE DE CERGY PONTOISE (FR) | 2014-10-23 | — | — | US | disclosed |
| EP-2604281-B1 | Clicked somatostatin conjugated analogs for biological applications | CENTRE NAT RECH SCIENT (FR) | 2014-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314670-A1 | CLICKED SOMATOSTATIN CONJUGATED ANALOGS FOR BIOLOGICAL APPLICATIONS | SSTR4, SSTR3, SSTR2 | OPRD1 3335/4885FOLH1 638/4885GRIN1 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.